Abstract 754P
Background
Ubamatamab (REGN4018) is a mucin16 (MUC16) x CD3 bispecific antibody. Cemiplimab, an anti-PD-1 antibody, enhanced its activity in preclinical studies. In phase 1 (NCT03564340), ubamatamab monotherapy resulted in an acceptable safety profile and durable responses. We now present ubamatamab combined with cemiplimab dose escalation results.
Methods
Patients (pts) with recurrent platinum-experienced ovarian cancer (OC) received weekly intravenous (IV) ubamatamab at a dose range of 1–450 mg after initial step-up dosing. Cemiplimab 350 mg IV every 3 weeks was added beginning Day 29–36. Dose escalation initially followed a modified 3+3 design, then Bayesian optimal interval design. Primary endpoints were safety and PK. Secondary endpoints included confirmed objective response rate (ORR), Kaplan-Meier estimated duration of response (DoR) and progression-free survival (PFS) (RECIST 1.1), and CA125 response (GCIG).
Results
35 pts were enrolled, 29 (82.9%) received ≥1 dose of cemiplimab. Median number of prior therapies was 5 (range 1−10). Median duration of ubamatamab and cemiplimab exposure was 11 (range 2−75) and 12 (3−69) weeks, respectively. The most common treatment-emergent adverse events (TEAE) were pain (82.9%) and cytokine release syndrome (68.6%, all Grade [G] 1/2). The most common G≥3 TEAE were anaemia (25.7%), pain (20.0%) and neutropaenia (11.4%, 1 dose-limiting toxicity [DLT], 60 mg). Ubamatamab 1–250 mg weekly with cemiplimab was tolerable. In the highest dose cohort (450 mg), haemophagocytic lymphohistiocytosis (G4, DLT) was observed. Objective responses were observed at ubamatamab doses 10–250 mg (n=25). In 22 of these pts receiving ≥1 dose of cemiplimab, ORR was 18.2% (95% CI: 5.2–40.3), median DoR 8.3 months (4.2–not estimable), CA125 response rate 22.7% (7.8–45.4) and 6-month PFS 47.6% (25.7–66.7). Two pts with target lesion growth (+17%, +31%) before adding cemiplimab to ubamatamab had subsequent partial responses. Ubamatamab PK was not impacted by cemiplimab.
Conclusions
In pts with heavily pretreated OC, an acceptable safety profile and durable responses were observed with ubamatamab + cemiplimab. A randomised phase 2 expansion of ubamatamab +/- cemiplimab is ongoing.
Clinical trial identification
NCT03564340.
Editorial acknowledgement
Writing assistance was provided by Brian Head, PhD, of Regeneron Pharmaceuticals, Inc.
Legal entity responsible for the study
Regeneron Pharmaceuticals, Inc.
Funding
Regeneron Pharmaceuticals, Inc.
Disclosure
R.E. O'Cearbhaill: Financial Interests, Personal, Other, Personal Fees: Bayer, Curio, Fresenius Kabi, Immunogen, MJH, Regeneron, Seattle Genetics, and Tesaro/GSK; Financial Interests, Personal, Other, Travel: Hitech Health ; Financial Interests, Personal, Advisory Board: GSK; Non-Financial Interests, Personal, Steering Committee Member: PRIMA, Moonstone (Tesaro/GSK) and DUO-O (AstraZeneca) studies; Non-Financial Interests, Personal, Advisory Role: Carina Biotech; Financial Interests, Institutional, Research Funding: AbbVie/StemCentrx, Atara Biotherapeutics, Bayer/Celgene/Juno, Genentech, Genmab/Seagen Therapeutics, Gynecologic Oncology Foundation , Kite Pharma, Ludwig Cancer Institute, Marker Therapeutics, Merck, Regeneron, Sellas Therapeutics, Syndax Pharmaceuticals, ; Financial Interests, Personal, Other, NRG representative: ComboMATCH study. K.N. Moore: Financial Interests, Personal, Advisory Board, Personal fees (consulting and/or advisory boards): Alkemeres, Aravive, AstraZeneca, Blueprint Pharma, Caris, Eisai, Elevar, Genentech/Roche, GSK/Tesaro, Hengrui, IMab, Immunogen, Inxmed, Iovance, Lilly, Mereo, Mersana, Myriad, Novartis, Novocure, Tarveda, VBL Therapeutics and Verastem; Financial Interests, Institutional, Research Funding: AbbVie, Artios, AstraZeneca, Daiichi Sankyo, Genentech/Roche, GSK/Tesaro, Immunogen, Lilly, Merck, Mereo, Novocure, PTC Therapeutics and Regeneron. O. Yeku: Financial Interests, Personal, Advisory Board: Celldex, GIMV NV, hC Bioscience and TigaTx. J.F. Liu: Financial Interests, Personal, Advisory Board, Personal fees (consulting and/or advisory boards): AstraZeneca, Clovis Oncology, Eisai, EpsilaBio, Genentech/Roche, GSK and Regeneron Pharmaceuticals, Inc.; Financial Interests, Institutional, Research Funding: 2X Oncology, Aravive, Arch Oncology, AstraZeneca, Bristol Myers Squibb, Clovis Oncology, CytomX Therapeutics, GSK, Regeneron, Surface Oncology, Tesaro, Vigeo Therapeutics and Zentalis. S. Bouberhan: Financial Interests, Personal, Speaker, Consultant, Advisor: ImmunoGen. E.P. Hamilton: Financial Interests, Institutional, Research Grant: Regeneron, AbbVie, Acerta Pharma, ADC Therapeutics, Akesobio Australia, Amgen, Aravive, ArQule, Arvinas, AstraZeneca, AtlasMedX, Black Diamond, Boehringer Ingelheim, Clovis, Compugen, Curis, CytomX, Dana Farber Cancer Inst, Daiichi Sankyo, Deciphera, eFFE; Financial Interests, Institutional, Speaker, Consultant, Advisor: Arcus, Arvinas, AstraZeneca, Black Diamond, Boehringer Ingelheim, CytomX, Daiichi Sankyo, Dantari, Deciphera Pharmaceuticals, Eisai, H3 Biomedicine, iTeos, Janssen, Lilly, Loxo, Merck, Mersana, Novartis, Pfizer, Puma Biotechnology, Relay Therapeutics, Roc. S. Yoo, S. Govindraj, J. Brouwer-Visser, M. Peterman, T. Schmidt, B. Barnes, P. Madia, M. Zhu, T.S. Uldrick, E.A. Miller: Financial Interests, Personal, Full or part-time Employment: Regeneron Pharmaceuticals, Inc.; Financial Interests, Personal, Stocks/Shares: Regeneron Pharmaceuticals, Inc. D. O'Malley: Financial Interests, Personal, Research Funding: AbbVie, Agenus, Amgen, AstraZeneca, Celsion Corp, Clovis, Corcept Therapeutics, Eisai, GOG Foundation , Immunogen, Iovance, Janssen/Johnson & Johnson, Mersana, Novocure and Genentech/Roche, Regeneron, SDP Oncology (BBI), Seagen and Tesaro/GSK, Ajinomoto Inc., Array Biopharma, Bristol Myers Squibb Co., Cerulean Pharma, EMD Serono, Ergomed, Inc. Research, Inc., inVentiv Health Clinical PRA Intl, Ludwig Cancer Research, Merck and GenMab, New Mexico Cancer Care Alliance, Serono Inc., Stemcentrx, Inc; Financial Interests, Personal, Advisory Board, Personal fees (consulting and/or advisory boards): Ambry, Arquer Diagnostics, Elevar, INXMED, Myriad Genetics, Novartis, Rubis, Roche Diagnostics MSA, Sorrento, Takeda, Tarveda and Toray, AbbVie, Agenus, Amgen, AstraZeneca, Celsion Corp, Clovis, Corcept Therapeutics, Eisai, GOG Foundation, Immunogen, Iovance, Janssen/Johnson & Johnson, Mersana, Novocure and Genentech/Roche, Regeneron, SDP Oncology (BBI), Seagen and Tesaro/GSK. All other authors have declared no conflicts of interest.
Resources from the same session
769P - Pharmacokinetic boosting of olaparib: An open-label, prospective, cross-over study
Presenter: Joanneke Overbeek
Session: Poster session 11
770P - Tolerability and efficacy of trabectedin plus pegylated liposomal doxorubicin (PLD) in elderly patients with ovarian cancer (OC): GEICO 105-O study
Presenter: Maria Jesus Rubio Perez
Session: Poster session 11
771P - Genomic characterization of advanced endometrial carcinosarcoma: Identification of potentially actionable targets
Presenter: Ugo De Giorgi
Session: Poster session 11
773P - Real-world results of homologous recombination deficiency testing: Comparison between two methods on 2,655 ovarian cancer patients in Spain
Presenter: Conxi Lazaro
Session: Poster session 11
774P - CCNE1 amplification defines a good prognostic subgroup among BRCAwt/HRDneg advanced high-grade ovarian cancer (HGOC)
Presenter: Felix Blanc-Durand
Session: Poster session 11
775P - A gene expression signature to predict benefit from intraperitoneal (IP) carboplatin chemotherapy in ovarian carcinoma (OC): Translational research study from the intraperitoneal therapy for ovarian cancer with carboplatin (iPocc) phase II/III trial
Presenter: David SP Tan
Session: Poster session 11
776P - Multi-omics analysis of chemo-refractory high-grade serous carcinoma patients: Insights from the DECIDER study
Presenter: Daria Afenteva
Session: Poster session 11
777P - Targeting cadherin-6 in epithelial ovarian cancer: Clinical significance of its expression and efficacy of raludotatug deruxtecan (R-DXd) in patient-derived cell models
Presenter: Daisuke Shintani
Session: Poster session 11
778P - Combined targeting poly (ADP-ribose) polymerase and receptor tyrosine kinase inhibits ovarian clear cell carcinoma progression via disrupted ribosomal biogenesis
Presenter: Chyong-Huey Lai
Session: Poster session 11
779P - Assessment of the RAD51 test to determine homologous recombination deficiency (HRD) in patients (pts) with newly diagnosed advanced high-grade epithelial ovarian cancer carcinoma (HGOC)
Presenter: Carmen Garcia Duran
Session: Poster session 11